Zonisamide vs Lamotrigine Er — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Anti-epileptic Agent

Zonisamide

Brand: ZONISADE

First FDA approval: 2000-03-27

Anti-epileptic Agent

Lamotrigine Er

First FDA approval: 2023-05-03

Lowest NADACAcquisition cost floor across all NDCs

$0.063Per unit

$0.371Per unit

Average NADACAcross all dosage forms and strengths

$0.186Up to $2.75

$0.828Up to $1.28

Generic manufacturersActive ANDA holders — FDA Orange Book

721 total ANDAs filed

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$57.9MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

640K141K beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$91Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

235Substantial friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

40Limited friction

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes7 manufacturers

NoBrand-only